Scott Hansen

Dr. Hansen has 25 years of experience in the field of virology and immunology, 17 of which were focused on the development and utilization of the non-human primate (NHP) model for the study of host vs. pathogen interactions, disease state modeling, and vaccine development. He is currently an Associate Professor at OHSU, where he has earned recognition for his strong publication record. The majority of this published work focused on the development of a novel vaccine platform based on Cytomegalovirus. To support the translation of this vector platform to clinical development and to provide sample intake functions for clinical trial endpoint analysis, Dr. Hansen developed a Human Samples Laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP), as well as a Quality System to provide appropriate regulation for documents, data, and inventory. He will draw upon this experience and expertise in his role at CytoDyn, where he will provide research support for method of action and assay support for clinical trials. Dr. Hansen’s research laboratory has been studying leronlimab since the Spring of 2021. In this time he has developed numerous flow cytometry biomarker assays to investigate how leronlimab/CCR5 modulates various immune cell phenotypes. Additionally, he developed an exploratory CCR5 receptor occupancy assay to evaluate leronlimab binding/loading after dosing. Dr. Hansen’s work has led to two research publications (one pending publication) that has already furthered CytoDyn’s understanding on the mechanism of action and potential applications of leronlimab in NASH and oncology.